Novo Holdings A S Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Novo Holdings A S boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 963,663 shares of the biopharmaceutical company's stock after purchasing an additional 113,663 shares during the period. Celldex Therapeutics comprises approximately 1.6% of Novo Holdings A S's investment portfolio, making the stock its 18th biggest holding. Novo Holdings A S owned approximately 1.45% of Celldex Therapeutics worth $32,755,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Celldex Therapeutics by 19.8% in the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company's stock worth $153,215,000 after purchasing an additional 604,251 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company's stock worth $129,571,000 after acquiring an additional 2,664,915 shares during the period. Bellevue Group AG boosted its stake in shares of Celldex Therapeutics by 15.7% during the 1st quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company's stock worth $117,374,000 after acquiring an additional 380,319 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of Celldex Therapeutics by 51.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company's stock valued at $71,725,000 after acquiring an additional 654,194 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Celldex Therapeutics by 53.3% in the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company's stock valued at $50,995,000 after purchasing an additional 479,068 shares in the last quarter.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX traded down $1.18 during mid-day trading on Friday, reaching $26.95. The company's stock had a trading volume of 618,496 shares, compared to its average volume of 851,896. The stock has a market capitalization of $1.78 billion, a P/E ratio of -9.46 and a beta of 1.55. Celldex Therapeutics, Inc. has a 1-year low of $22.11 and a 1-year high of $53.18. The stock has a 50-day moving average of $35.82 and a two-hundred day moving average of $36.68.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.05. The business had revenue of $2.50 million for the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. Analysts predict that Celldex Therapeutics, Inc. will post -2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CLDX has been the topic of several research analyst reports. The Goldman Sachs Group started coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a "neutral" rating and a $45.00 price objective on the stock. Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. Citigroup started coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $70.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, September 26th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $62.25.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.